{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"SBP, <90 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"SBP, 90 to 139 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"}]}],"title":"SBP, 140 to 169 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"SBP, >=170 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"DBP, <90 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"DBP, 90 to 139 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46"}]}],"title":"DBP, 140 to 169 mmHg"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"DBP, >=170 mmHg"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Blood pressure measurements included systolic blood pressure (SBP, millimeters of mercury \\[mmHg\\]) and diastolic BP (DBP). The number of participants with a post-Baseline shift from Baseline in blood pressure (\\<90 mmHg, 90 to 139 mmHg, 140 to 169 mmHg, \\>=170 mmHg) was assessed.","groups":[{"description":"Participants received pazopanib 800 milligrams (mg) once daily.","id":"OG000","title":"Pazopanib 800 mg"}],"paramType":"NUMBER","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From Baseline to investigational product discontinuation (up to 6.230 years)","title":"Number of Participants With the Indicated Shift From Baseline in Blood Pressure at Any Time Post-Baseline","type":"PRIMARY","unitOfMeasure":"participants"}